Akorn, Inc. has received approval for a supplemental new drug application (SNDA) approval for Inapsine injection. Akorn is the NDA holder of this drug product, which has been off the market since 2001 due to compliance issues associated with Akorn’s Decatur manufacturing facility. Akorn recently was awarded a contract for Inapsine from Premier Purchasing Partners, LP, a hospital group purchasing organizations. The award is effective July 1, 2006. Arthur S. Przybyl, Akorn’s president ...